Cystitis in Women: Focus

Urinary tract infections are one of the most common conditions in medical practice, especially in general medicine. Whether it is uncomplicated adolescent cystitis after first sexual intercourse, postmenopausal infection or recurrent cystitis at any age, lower urinary tract infection disrupts the quality of life for many women. Despite the often multifactorial origin, each woman has a very specific reason for developing cystitis and it is necessary to look for the trigger (s) [1]. The reason for consultation is most often simple dysuria (difficulty voiding), but can also present in 2 to 5% of cases in the form of urgency voiding or pollakiuria [2]. The prevalence figures for acute uncomplicated urinary tract infection range from 30 to 50 per thousand in adult women [3]. As the risk of urinary tract infection increases with age, half of women develop symptomatic infection at least once [4], but only half of them will see them [5]. However, apart from the significant physical and psychological disturbances that can cause a urinary tract infection, especially recurrent, it should be known that there is no medical condition which requires so many consultations, bacteriological examinations and antibiotic prescriptions than cystitis [6].

Author(s):  
Андрей Владимирович Кузьменко ◽  
Владимир Васильевич Кузьменко ◽  
Тимур Асланбекович Гяургиев ◽  
Мария Николаевна Химичева ◽  
Наталья Ивановна Кузьмина

Острый цистит является самым частым проявлением неосложненной инфекции мочевых путей. Одним из препаратов, чья эффективность в лечении больных с ИНМП доказана, является фосфомицин, который в течение длительного времени широко применяется в урологической практике. Несмотря на хорошие результаты этиотропной терапии, неразрешенной остается проблема рецидивирования ИМП. У каждой 3 женщины к 24 годам в анамнезе имеется эпизод острого цистита которая возникает примерно у 30% женщин в течении года после первого эпизода цистита. Частое рецидивирование данного заболевания влечет за собой существенные последствия, затрагивающие все сферы жизни женщины, практически парализуя ежедневный распорядок дня. Ярко выраженные симптомы, такие как постоянные позывы к мочеиспусканию, рези при мочеиспускании лишают трудоспособности, полноценного ночного сна и половой жизни. Ограничивают возможность свободного передвижения, что необходимо учитывать, особенно в постоянно растущем ритме жизни. Это создает необходимость в поиске средств, продляющих безрицидивный период, тем самым снижая отрицательное влияние данного заболевания на жизнь пациенток Альтернативные профилактические средства, находят все более широкое применение. Одним из таких средств является D-манноза. В данном исследовании была проведена оценка эффективности терапии фосфомицином с обогащением рациона питания источником D - маннозы и фосфомицина - в комплексном лечении женщин с неосложненной инфекцией нижних мочевых путей Acute cystitis is the most common manifestation of uncomplicated urinary tract infection. One of the drugs whose effectiveness in the treatment of patients with INMP has been proven is fosfomycin, which has been widely used in urological practice for a long time. Despite the good results of etiotropic therapy, the problem of recurrent UTI remains unresolved. Every 3 women have a history of acute cystitis by the age of 24, which occurs in approximately 30% of women within a year after the first episode of cystitis. Frequent recurrence of this disease entails significant consequences that affect all areas of a woman's life, practically paralyzing the daily routine. Pronounced symptoms, such as constant urge to urinate, pain when urinating, deprive the ability to work, a full night's sleep and sexual activity. They restrict the possibility of free movement, which must be taken into account, especially in the ever-growing pace of life. This creates the need to search for means that extend the disease-free period, thereby reducing the negative impact of this disease on the lives of patients. Alternative preventive means are becoming more widely used. One such remedy is D-mannose. In this study, we evaluated the effectiveness of fosfomycin therapy with a source of D - mannose and fosfomycin in the complex treatment of women with uncomplicated lower urinary tract infection


1983 ◽  
Vol 11 (6) ◽  
pp. 375-379 ◽  
Author(s):  
J B Sutton

In a multicentre general practice study 158 females with acute, uncomplicated urinary tract infection received a 5-day course of pivampicillin 500 mg twice-daily (Pondocillin). Significant bacteriological cultures were obtained from forty-one patients before treatment and the original organism was eradicated in thirty-eight of these patients (93%). The mean symptom score was reduced from 7·33 to 1·18. Eleven patients (7%) reported side-effects. One patient ceased treatment after 4 days due to a rash. Pivampicillin, in a convenient twice-daily regimen, was confirmed as an effective treatment for acute lower urinary tract infection.


PEDIATRICS ◽  
1974 ◽  
Vol 54 (5) ◽  
pp. 619-621
Author(s):  
Calvin M. Kunin

There is ample evidence that significant bacteriuria is frequent enough and procedures for mass screening are sufficiently developed to enable this country to mount a large scale program directed to the early detection of urinary tract infections. Information is now available on the epidemiology of bacteriuria, the frequency of associated structural abnormalities and methods to provide effective management. It is also clear that most female children with urinary tract infection generally will have a good prognosis. Few will develop endstage renal failure, but symptomatic infection is commonly associated with considerable morbidity. Unfortunately, it is not as yet possible to predict which child is at high risk of developing serious complications without searching for structural or neurologic abnormalities or by following individual patterns of recurrence. The ultimate impact on health and longevity is unknown even using data from the most structured programs. There is also the danger that mass programs may lead to false hope and eventual disillusionment if they are limited to detect infection and do not provide for further diagnostic, therapeutic and long-term follow-up of patients. For these reasons, urinary tract infection detection programs must be designed in relation to the realities of the current medical care system, the goals should be clearly defined and the expected result be stated honestly. AIMS OF THE PROGRAM There are two major reasons for screening children for urinary tract infection. One is to prevent the considerable morbidity from symptomatic infection and its complications so common in females throughout life. The other is to detect the population (often with anatomical abnormalities) at risk of developing pyelonephritis and subsequent renal damage.


Author(s):  
George G. Zhanel ◽  
Michael A. Zhanel ◽  
James A. Karlowsky

Oral fosfomycin is approved in Canada for the treatment of acute uncomplicated cystitis. Several studies have reported “off label” use of oral fosfomycin in the treatment of patients with complicated lower urinary tract infection (cLUTI). This review summarizes the available literature describing the use of oral fosfomycin in the treatment of patients with cLUTI. Collectively, these studies support the use of a regimen of 3 grams of oral fosfomycin administered once every 48 or 72 hours for a total of 3 doses for patients who have previously failed treatment with another agent, are infected with a multidrug-resistant (MDR) pathogen, or cannot tolerate first-line treatment due to intolerance or adverse effects. Additionally, a Phase 2/3 clinical trial, known as the ZEUS study, assessed the efficacy and safety of intravenous (IV) fosfomycin versus piperacillin-tazobactam in the treatment of patients with complicated upper urinary tract infection (cUUTI) or acute pyelonephritis (AP) including in patients with concomitant bacteremia. IV fosfomycin was reported to be noninferior to piperacillin-tazobactam in treating patients with cUUTI and AP; however, when outcomes were independently evaluated according to baseline diagnosis (i.e., cUUTI versus AP), IV fosfomycin was superior to piperacillin-tazobactam in the treatment of patients with cUUTI and demonstrated superior microbiological eradication rates, across all resistant phenotypes including extended-spectrum β-lactamase- (ESBL-) producing Escherichia coli and Klebsiella spp. and carbapenem-resistant (CRE), aminoglycoside-resistant, and MDR Gram-negative bacilli (primarily Enterobacterales). Based on the ZEUS study, IV fosfomycin dosed at 6 grams every 8 hours for 7 days (14 days in patients with concurrent bacteremia) appears to be a safe and effective therapeutic option in treating patients with upper urinary tract infections, particularly those with cUUTI caused by antimicrobial-resistant Enterobacterales.


1981 ◽  
Vol 15 (11) ◽  
pp. 863-866
Author(s):  
Randall A. Prince ◽  
Deborah H. Cassel ◽  
Charles D. Hepler ◽  
James L. Wilson ◽  
Mark E. Jones ◽  
...  

Traditionally, the therapeutic regimen of sulfisoxazole in acute urinary tract infection has included either a 2- or 4-g loading dose. However, the biopharmaceutical aspects of this drug indicate that a loading dose is unnecessary. The objective of this clinical study, therefore, was to compare a traditional regimen of sulfisoxazole to a regimen not utilizing a loading dose. Fifty adult female patients with acute, uncomplicated urinary tract infections were assigned to a ten-day course of sulfisoxazole 1 g po qid. Patients were randomly allocated to a 2-g loading dose or no loading dose regimen. Data were analyzed with regard to resolution of presenting symptoms and eradication of the infecting organism (i.e., cure). Statistical analysis demonstrated no significant difference for symptom resolution and cure. It appears that the convention of using an initial 2-g oral loading dose of sulfisoxazole in the treatment of acute, uncomplicated urinary tract infection is unwarranted.


2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S792-S793
Author(s):  
Jeffrey Thompson ◽  
Alen Marijam ◽  
Fanny S Mitrani-Gold ◽  
Jonathon Wright ◽  
Ashish V Joshi

Abstract Background Uncomplicated urinary tract infections (uUTI) are generally treated empirically with antibiotics. However, antibiotic (AB) allergies limit the available oral treatment options for some patients. We assessed the proportion of self-reported AB allergies among US females with uUTI. Methods We performed a cross-sectional survey of US females ≥ 18 years of age with a self-reported urinary tract infection (UTI) in the 60 days prior to participation and a prescription of oral AB. Participants were further screened for evidence of a complicated urinary tract infection and, after exclusions, participants with a uUTI completed an online questionnaire about their most recent episode. Participants were from the Northeast (20%), Midwest (44%), South (20%), and West (16%) US. Descriptive self-reported allergy data were stratified into subgroups by whether the participant had recurrent UTI (defined as ≥ 2 uUTIs in the past 6 months or ≥ 3 uUTIs in past 12 months including index UTI), the number of different ABs given for the index episode (1, 2, ≥ 3), and whether the treatment was clinically appropriate according to Infectious Diseases Society of America uUTI guidelines. Results Overall, 375 female participants completed the questionnaire. The most commonly prescribed ABs for participants’ most recent uUTI were trimethoprim-sulfamethoxazole (TMP-SMX; 38.7%), ciprofloxacin (22.7%), and nitrofurantoin (18.9%) (Table 1). Most participants received only 1 AB for their uUTI (62.7%) and the majority were classified as having a non-recurrent uUTI (56.5%). No AB allergies were reported for most participants (69.3%); overall, 24.0% reported 1 AB allergy and 6.7% reported ≥ 2. A higher proportion of participants reported ≥ 2 allergies in the recurrent uUTI, ≥ 3 AB, and multiple AB subgroups (Table 2). The most common allergy was to TMP-SMX (15.7%), followed by amoxicillin-clavulanate (8.3%) and ciprofloxacin (5.3%) (Table 2). Similar allergy trends were seen across subgroups, except higher rates of ciprofloxacin allergy were seen in participants given multiple ABs (Table 2). Table 1. Antibiotics used to treat most recent uUTI Table 2 . Frequency of antibiotic allergies across cohort subgroups Conclusion AB allergies were relatively frequent in this uUTI cohort and the most common allergy was to TMP-SMX, which was the most prescribed AB. Allergies to ABs reduce the available treatment options for uUTI in some patients. Disclosures Jeffrey Thompson, PhD, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Alen Marijam, MSc, GlaxoSmithKline plc. (Employee, Shareholder) Fanny S. Mitrani-Gold, MPH, GlaxoSmithKline plc. (Employee, Shareholder) Jonathon Wright, BSc, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Ashish V. Joshi, PhD, GlaxoSmithKline plc. (Employee, Shareholder)


2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S155-S155
Author(s):  
Alvaro Otreras ◽  
Sofia Sabato ◽  
Daniela D′Alessandro ◽  
Sylvia Errea ◽  
Edgardo Bottaro ◽  
...  

Abstract Background Uncomplicated urinary tract infection (uUTI) is one of the main causes of antibiotics prescription in outpatient setting. Current recommendations, based on studies from pre-antimicrobial resistance era, suggest that diagnosis of uUTI can be made based on clinical symptoms and that urine analysis leads only to a minimal increase in diagnostic accuracy. We analyzed urine cultures (UC) from patients with clinical diagnosis. Methods Prospective and observational study carried out in an Emergency Department during August 2016 to August 2017. Women older than 15 years with 2 or more classic symptoms of uUTI and the absence of vaginal discharge and irritation were included. Those with complicated and recurrent urinary tract infection (UTI) were excluded. Urine cytology and UC were performed in all episodes. A bivariate and multivariate analysis was performed considering the probability of having a positive urine culture according to the different symptomatology variables. Results We enrolled 208 patients, with a median age of 25 (14-68 years). Previous UTI 6 (2.9%), previous antibiotic (last 3 months) 20 (9.6%). Inflammatory cytology 173 (83.2%), positive UC 109 (52.4%), cystitis 155 (74.5%). Symptoms: dysuria 154 (74%), frequency 111 (53.4%), tenesmus 97 (46.6%), fever 78 (37.5%), hematuria 43 (20, 7%), hypogastric pain 128 (61.5%), back pain 84 (40.4%). Combinations of 3 or more classic symptoms occurred in 52 (25%) episodes. The most frequent association was dysuria, frequency and tenesmus. No statistically significant association was found either in the bivariate or multivariate analysis in relation to presenting positive UC (Tables 1 and 2). Conclusion The results show that almost 50% of the patients with a clinical diagnosis of UTI had a negative urine culture. We consider it necessary to rethink the prescription of antibiotics without microbiological confirmation in the first episode of uUTI as a strategy to reduce inappropriate use of antibiotics. Disclosures All Authors: No reported disclosures


1979 ◽  
Vol 1 (5) ◽  
pp. 131-131
Author(s):  
A. W. ASSCHER

As pointed out by Dr Rapkin in this issue (p 133), urinary tract infections are a common cause of morbidity in childhood. In the Swedish town of Göteborg, with about 500,000 inhabitants, all new urinary tract infections were studied over a seven-year period, and it was shown that the risk of acquiring symptomatic infections for boys up to the age of 11 was 1.1% and for girls 3%. Naturally the question arises whether screening for symptomless infection could prevent this high morbidity. To answer this question it is essential to know whether symptomless infections lead to symptomatic infection and if so whether treatment, suitable for use on a large scale, could prevent the development of symptoms.


Sign in / Sign up

Export Citation Format

Share Document